Published in Oncogene on April 20, 2009
NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem (2010) 1.20
The c-Rel Transcription Factor in Development and Disease. Genes Cancer (2011) 1.01
Identification of an NF-κB p50/p65-responsive site in the human MIR155HG promoter. BMC Mol Biol (2013) 0.91
The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS One (2013) 0.89
The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia. Leukemia (2013) 0.89
Annotation enrichment analysis: an alternative method for evaluating the functional properties of gene sets. Sci Rep (2014) 0.87
Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget (2015) 0.84
A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity. Cancer Lett (2011) 0.81
The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma. Oncogene (2015) 0.80
Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth. Mol Cancer (2014) 0.80
Bcl-XL, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis. Cancer Lett (2011) 0.79
Cell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-kappaB oncogenesis. Oncogene (2010) 0.78
Inhibition of Oncogenic Transcription Factor REL by the Natural Product Derivative Calafianin Monomer 101 Induces Proliferation Arrest and Apoptosis in Human B-Lymphoma Cell Lines. Molecules (2015) 0.76
Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas. Oncogene (2016) 0.76
Artificial antigen-presenting cells expressing AFP158-166 peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes. Oncotarget (2016) 0.75
Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma. Leuk Lymphoma (2016) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 7.57
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell (1991) 7.40
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Matrix2png: a utility for visualizing matrix data. Bioinformatics (2003) 5.31
Mining for regulatory programs in the cancer transcriptome. Nat Genet (2005) 2.88
Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol (2002) 2.37
Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. J Virol (1992) 2.26
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol (2006) 2.02
Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood (1992) 1.81
Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood (2003) 1.74
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood (2005) 1.59
Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol (2006) 1.42
Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci U S A (2008) 1.42
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene (1999) 1.41
Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci U S A (2004) 1.39
The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene (2004) 1.39
LMP1 strain variants: biological and molecular properties. J Virol (2006) 1.35
Liver-specific hepatocyte nuclear factor-4alpha deficiency: greater impact on gene expression in male than in female mouse liver. Mol Endocrinol (2008) 1.30
Role of STAT5a in regulation of sex-specific gene expression in female but not male mouse liver revealed by microarray analysis. Physiol Genomics (2007) 1.20
Regulation of nuclear factor kappa B transactivation. Implication of phosphatidylinositol 3-kinase and protein kinase C zeta in c-Rel activation by tumor necrosis factor alpha. J Biol Chem (2001) 1.19
Malignant transformation of B lymphoma cell line BJAB by Epstein-Barr virus-encoded small RNAs. FEBS Lett (2000) 1.19
Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma. Haematologica (2008) 1.15
Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood (2003) 1.13
Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation. Proc Natl Acad Sci U S A (1999) 1.07
The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway. Oncogene (2002) 1.06
Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proc Natl Acad Sci U S A (2004) 0.99
Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability. Oncogene (2005) 0.99
Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene (2003) 0.99
Relationship between the amounts of EBV-DNA and EBNA per cell, clonability and tumorigenicity in two ebv-negative lymphoma lines and their EBV-converted sublines. Int J Cancer (1983) 0.99
Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-kappaB have a malignantly transformed phenotype. Oncogene (2002) 0.98
Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity. Oncogene (2006) 0.97
Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL. Oncogene (2008) 0.90
Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins. Cancer Res (2008) 0.89
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol (2006) 0.89
Conversion of the lymphoma line "BJAB" by Epstein-Barr virus into phenotypically altered sublines is accompanied by increased c-myc mRNA levels. Int J Cancer (1987) 0.89
Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood (1998) 0.88
Regulation of adhesion and growth of fibrosarcoma cells by NF-kappa B RelA involves transforming growth factor beta. Mol Cell Biol (1994) 0.88
Stable expression of the avian retroviral oncoprotein v-Rel in avian, mouse, and dog cell lines. Virology (2003) 0.87
Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes Chromosomes Cancer (2002) 0.86
Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor kappaB by inhibiting the inhibitor of kappaB kinase. Mol Pharmacol (2003) 0.86
Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics. Annu Rev Biochem (1983) 6.24
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics (1996) 6.12
The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol (1993) 4.92
Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene (1999) 4.76
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol (2001) 4.66
Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A (1997) 4.11
Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene (2006) 3.49
Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ (2006) 3.04
Cerebral metabolic suppression during hypothermic circulatory arrest in humans. Ann Thorac Surg (1999) 2.90
Localization of the G protein betagamma complex in living cells during chemotaxis. Science (2000) 2.87
An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A (2001) 2.83
Dynamic distribution of chemoattractant receptors in living cells during chemotaxis and persistent stimulation. J Cell Biol (1997) 2.78
Interaction between ATM protein and c-Abl in response to DNA damage. Nature (1997) 2.70
Intensive care unit telemedicine: alternate paradigm for providing continuous intensivist care. Crit Care Med (2000) 2.50
Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene (2006) 2.33
Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem (1986) 2.31
Child health, developmental plasticity, and epigenetic programming. Endocr Rev (2010) 2.15
A genetic linkage map of the bovine genome. Nat Genet (1994) 2.15
vRel is an inactive member of the Rel family of transcriptional activating proteins. J Virol (1991) 2.04
Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by REV-T. Cell (1986) 1.96
4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. J Med Chem (2000) 1.94
Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci U S A (1998) 1.81
Cloning and expression of a chicken c-rel cDNA: unlike p59v-rel, p68c-rel is a cytoplasmic protein in chicken embryo fibroblasts. Oncogene (1990) 1.80
Temporal relationship between the sexually dimorphic spontaneous GH secretory profiles and hepatic STAT5 activity. Endocrinology (2001) 1.74
Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res (1993) 1.73
trans-Activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals. Toxicol Appl Pharmacol (1999) 1.72
Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol (2001) 1.58
SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem (1999) 1.56
Sequence of active site peptides from the penicillin-sensitive D-alanine carboxypeptidase of Bacillus subtilis. Mechanism of penicillin action and sequence homology to beta-lactamases. J Biol Chem (1980) 1.53
Mechanism of penicillin action: penicillin and substrate bind covalently to the same active site serine in two bacterial D-alanine carboxypeptidases. Proc Natl Acad Sci U S A (1979) 1.53
Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats. Alcohol Clin Exp Res (1994) 1.51
Tyrosine phosphorylation of a 50K cellular polypeptide associated with the Rous sarcoma virus transforming protein pp60src. Mol Cell Biol (1982) 1.49
STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology (2001) 1.47
Involvement of apoptosis in neurological injury after hypothermic circulatory arrest: a new target for therapeutic intervention? Ann Thorac Surg (2001) 1.47
Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry (1985) 1.46
Hospital expenditures and utilization: the impact of HMOs. Am J Manag Care (1999) 1.45
Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms. Oncogene (1997) 1.42
Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J Biol Chem (1983) 1.37
Transforming function of the HOX11/TCL3 homeobox gene. Cancer Res (1997) 1.36
Metabolic compartmentation of glutamate and glutamine: morphological evidence obtained by quantitative immunocytochemistry in rat cerebellum. Neuroscience (1992) 1.36
The C terminus of the NF-kappa B p50 precursor and an I kappa B isoform contain transcription activation domains. Nucleic Acids Res (1992) 1.36
Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem (1997) 1.35
LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochim Biophys Acta (2001) 1.33
Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos (1999) 1.30
A protein kinase-A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel. Mol Cell Biol (1991) 1.29
Phosphorylation of IkappaB-alpha inhibits its cleavage by caspase CPP32 in vitro. J Biol Chem (1997) 1.25
Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene (1999) 1.24
p105, the NF-kappa B p50 precursor protein, is one of the cellular proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells. J Virol (1992) 1.24
Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol (2000) 1.24
Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption. J Biol Chem (1999) 1.20
Chronic rhinosinusitis and asthma: novel understanding of the role of IgE 'above atopy'. J Intern Med (2012) 1.20
Snm1B/Apollo mediates replication fork collapse and S Phase checkpoint activation in response to DNA interstrand cross-links. Oncogene (2008) 1.20
Primary structure of the COOH-terminal membranous segment of a penicillin-sensitive enzyme purified from two Bacilli. J Biol Chem (1981) 1.20
Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochem Pharmacol (1994) 1.19
Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys (1995) 1.19
Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos (1997) 1.18
Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol (2011) 1.18
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics (1997) 1.18
Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy (2012) 1.17
Phenobarbital-induced rat liver cytochrome P-450. Purification and characterization of two closely related isozymic forms. J Biol Chem (1982) 1.15
Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase. J Biol Chem (1999) 1.15
Alternatively activated macrophages and impaired phagocytosis of S. aureus in chronic rhinosinusitis. Allergy (2010) 1.14
Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy (2012) 1.13
Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1. J Virol (1994) 1.12
Cytochrome P-450 enzyme-specific control of the regio- and enantiofacial selectivity of the microsomal arachidonic acid epoxygenase. J Biol Chem (1990) 1.12
Stress and IL-1beta contribute to the development of depressive-like behavior following peripheral nerve injury. Mol Psychiatry (2009) 1.12
Rat hepatic cytochrome P-450 isoenzyme 2c. Identification as a male-specific, developmentally induced steroid 16 alpha-hydroxylase and comparison to a female-specific cytochrome P-450 isoenzyme. J Biol Chem (1984) 1.11
Plasma growth hormone pulse activation of hepatic JAK-STAT5 signaling: developmental regulation and role in male-specific liver gene expression. Endocrinology (2000) 1.10
Penicillins and cephalosporins are active site-directed acylating agents: evidence in support of the substrate analogue hypothesis. Philos Trans R Soc Lond B Biol Sci (1980) 1.10
Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. Mol Pharmacol (1996) 1.10
Mechanisms of multiple organ damages in acute necrotizing pancreatitis. Chin Med J (Engl) (2001) 1.10
Regulation of signal transducer and activator of transcription (STAT) 5b activation by the temporal pattern of growth hormone stimulation. Mol Endocrinol (1997) 1.10
Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys (1994) 1.09
Sex-specific, growth hormone-regulated transcription of the cytochrome P450 2C11 and 2C12 genes. J Biol Chem (1992) 1.08
Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis - a GALEN study. Allergy (2009) 1.08
Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res (1997) 1.08
Synergistic action of hepatocyte nuclear factors 3 and 6 on CYP2C12 gene expression and suppression by growth hormone-activated STAT5b. Proposed model for female specific expression of CYP2C12 in adult rat liver. J Biol Chem (2000) 1.08
Retrograde cerebral perfusion provides negligible flow through brain capillaries in the pig. J Thorac Cardiovasc Surg (2001) 1.08
v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence. Oncogene (1993) 1.07
Growth hormone, but not prolactin, maintains, low-level activation of STAT5a and STAT5b in female rat liver. Endocrinology (1999) 1.07
Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone. J Biol Chem (2000) 1.07
Cleavage of a COOH-terminal hydrophobic region from D-alanine carboxypeptidase, a penicillin-sensitive bacterial membrane enzyme. Characterization of active, water-soluble fragments. J Biol Chem (1979) 1.07
Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat (2009) 1.06
Gamma-aminobutyric acid up- and downregulates insulin secretion from beta cells in concert with changes in glucose concentration. Diabetologia (2006) 1.06
The v-Rel oncoprotein blocks apoptosis and proteolysis of I kappa B-alpha in transformed chicken spleen cells. Oncogene (1995) 1.06
Mechanisms of cyclophosphamide action on hepatic P-450 expression. Cancer Res (1990) 1.05
Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy. J Endocrinol Invest (2008) 1.05
STAT5b-deficient mice are growth hormone pulse-resistant. Role of STAT5b in sex-specific liver p450 expression. J Biol Chem (1999) 1.04
The NS3 proteins of global strains of bluetongue virus evolve into regional topotypes through negative (purifying) selection. Vet Microbiol (2007) 1.04
The ties that bind what is known to the recall of what is new. Psychon Bull Rev (2000) 1.04
Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol (2001) 1.03
Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain. Oncogene (1993) 1.03
Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res (1998) 1.03
Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia (2011) 1.03
Amino acid sequence homologies between Escherichia coli penicillin-binding protein 5 and class A beta-lactamases. FEBS Lett (1982) 1.02